Strontium ranelate in post-menopausal osteoporosis

Endokrynologia Polska

Volumn 62, Issue 1, 2011, Pages 65-72

  Przedlacki, Jerzy ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Osteoporosis; Strontium ranelate; Treatment

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PARATHYROID HORMONE[1-34]; PLACEBO; SOMATOMEDIN C; STRONTIUM RANELATE;

AMNESIA; BONE DENSITY; BONE METABOLISM; BONE MINERAL; COMPUTER ASSISTED TOMOGRAPHY; CONSCIOUSNESS DISORDER; CONVULSION; COST EFFECTIVENESS ANALYSIS; DERMATITIS; DIARRHEA; DRESS SYNDROME; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INFORMATION; DRUG MECHANISM; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; HEADACHE; HIP; HIP FRACTURE; HUMAN; LOOSE FECES; LUMBAR SPINE; NAUSEA; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; REVIEW; SEIZURE; SYNCOPE; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 79953813752     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Chattopadhyay N, Quinn SJ, Kifor O et al. The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation. Biochem Pharmacol 2007; 74: 438-447. (Pubitemid 46970843)
2. Takaoka S, Yamaguchi T, Yano S et al. The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast differentiation and mineralisation. Horm Metab Res 2010; 42: 627-631.
3. Hurtel AS, Mentaverri R, Caudrillier A et al. The calcium-sensing receptor is involved in strontium ranelate-induced osteoclast apoptosis. New insights into the associated signalling pathways. J Biol Chem 2009; 284: 575-584.
4. Fromigue O, Hay E, Barbara A et al. Calcium sensing receptor-dependent and receptor-independent activation of osteoblast replication and survival by strontium ranelate. J Cell Mol Med 2009; 13: 2189-2199.
5. Atkins GJ, Welldon KJ, Halbout P et al. Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int 2009; 20: 653-664.
6. Gulhan I, Bilgili S, Gunaydin R et at al. The effect of strontium ranelate on serum insulin like growth factor-1 and leptin levels in osteoporotic post-menopausal women: a prospective study. Arch Gynecol Obstet 2008; 278: 437-441.
7. Meunier PJ, Slosman DO, Delmas PD et al. Strontium ranelate: dose-dependent effects in established post-menopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002; 87: 2060-2066. (Pubitemid 34521489)
8. Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with post-menopausal osteoporosis. N Engl J Med 2004; 350: 459-168.
9. Reginster JY, Seeman E, De Vernejoul MC et al. Strontium ranelate reduces the risk of nonvertebral fractures in post-menopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90: 2816-2822. (Pubitemid 40686329)
10. Bruyere O, Detilleux J, Decock C et al. Relationship between changes in bone mineral density and vertebral fracture incidence: an analysis of the last three years of an eight-year treatment with strontium ranelate. Osteoporos Int 2009; 20 (Suppl. 1): S11.
11. Ringe JD, Doherty JG. Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat. Rheumatol Int 2010; 30: 863-869.
12. Arlot ME, Jiang Y, Genant HK et al. Histomorphometric and microCT analysis of bone biopsies from post-menopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res 2008; 23: 215-222. (Pubitemid 351160035)
13. Roschger P, Manjubala I, Zoeger N et al. Bone material quality in transiliac bone biopsies of postmenopausal osteoporotic women after 3 years of strontium ranelate treatment. J Bone Miner Res 2010; 24: 891-900.
14. Chenghao L, Oskar P, Siegel S et al. Strontium is incorporated into mineral crystals only in newly formed bone during strontium ranelate treatment. Am J Bone Miner Res 2010; 25: 968-975.
15. Marguis P, Roux C, de la Loge C et al. Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis. Osteoporos Int 2008; 19: 503-510.
16. Seeman E, Boonen S, Borgstrom F et al. Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age. Bone 2010; 46: 1038-1042.
17. Recker RR, Marin F, Ish-Shalom S et al. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in post-menopausal women with osteoporosis. J Bone Miner Res 2009; 24: 1358-1368.
18. Seeman E, Vellas B, Benhamou C et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 2006; 21: 1113-1120.
19. Roux C, Fechtenbaum J, Kolta S et al. Strontium ranelate reduces the risk of vertebral fracture in young post-menopausal women with severe osteoporosis. Ann Rheum Dis 2008; 67: 1736-1738.
20. Reginster JY, Felsenberg D, Boonen S et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in post-menopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 2008; 58: 1687-1695. (Pubitemid 351847521)
21. Seeman E, Devogelaer JP, Lorenc R et al. Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J Bone Miner Res 2008; 23: 433-438. (Pubitemid 351304674)
22. Roux C, Reginster JY, Fechtenbaum J et al. Vertebral fracture risk reduction with strontium ranelate in women with post-menopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 2006; 21: 536-542.
23. Collette J, Bruyere O, Kaufman JM et al. Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover. Osteoporos Int 2010; 21: 233-241.
24. Reginster JY, Deroisy R, Dougados M et al. Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos Int 2002; 13: 925-931. (Pubitemid 36050269)
25. Bruyere O, Roux C, Detilleux J et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 2007; 92: 3076-3081. (Pubitemid 47236373)
26. Bruyere O, Collette J, Rizzoli R et al. Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for three years. Osteoporos Int 2010; 21: 1031-1036.
27. Hiligsmann M, Bruyere O, Register JY. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years. Bone 2010; 46: 440-446.
28. Hiligsmann M, Bruyere O, Register JY. Cost-utility of long-term strontium ranelate treatment for post-menopausal osteoporotic women. Osteoporos Int 2010; 21: 157-165.
29. Borgstrom F, Strom O, Coelho J et al. The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporos Int 2010; 21: 339-349.
30. Rizzoli R, Laroche M, Krieg MA et al. Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis. Rheumatol Int 2010; 30: 1341-1348.
31. Breart G, Cooper C, Meyer O et al. Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database. Osteoporos Int 2010; 21: 1181-1187.
32. Busse B, Jobke B, Hahn M et al. Effects of strontium ranelate administration on bisphosphonate-altered hydroxyapatite: matrix incorporation of strontium is accompanied by changes in mineralization and microstructure. Acta Biomater 2010; 6: 4513-4521.
33. Anastasilaksis AD, Polyzos SA, Avramidis A et al. Effect of strontium ranelate on lumbar spine mineral density in women with established osteoporosis previously treated with teriparatide. Horm Metab Res 2009; 41: 559-562.
34. Jonville-Bera AP, Crickx B, Aaron L et al. Strontium ranelate-induced DRESS syndrome: first two case reports. Allergy 2009; 64: 658-659.
35. Pernicova I, Middleton ET, Aye M. Rash, strontium ranelate and DRESS syndrome put into perspective. European Medicine Agency on the alert. Osteoporos Int 2008; 19: 1811-1812.
36. Smith EV, Shipley DR. Severe exfoliative dermatitis caused by strontium ranelate: two cases of a new drug reaction. Age Ageing 2010; 39: 401-403.
37. Osborne V, Layton D, Perrio N et al. Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England. Drug Suf 2010; 33: 579-591.